Kurt Oettel

Kurt Oettel

UNVERIFIED PROFILE

Are you Kurt Oettel?   Register this Author

Register author
Kurt Oettel

Kurt Oettel

Publications by authors named "Kurt Oettel"

Are you Kurt Oettel?   Register this Author

13Publications

276Reads

39Profile Views

A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study.

Invest New Drugs 2013 Aug 21;31(4):943-8. Epub 2012 Dec 21.

University of Wisconsin Carbone Cancer Center and the University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue, K6/548 CSC, Madison, WI 53792, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-012-9916-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4199231PMC
August 2013

Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer.

Lung Cancer 2013 Jul 28;81(1):138-41. Epub 2013 Apr 28.

Department of Medicine and Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2013.03.020DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3679338PMC
July 2013

Effect of medical castration on CYP3A4 enzyme activity using the erythromycin breath test.

Cancer Chemother Pharmacol 2008 Aug 9;62(3):373-7. Epub 2007 Oct 9.

School of Pharmacy, University of Wisconsin, 777 Highland Avenue, Madison, WI 53705, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-007-0613-6DOI Listing
August 2008

A morphealike skin condition caused by Borrelia burgdorferi in an immunocompromised patient.

Mayo Clin Proc 2006 Sep;81(9):1259-60, 1263

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4065/81.9.1259-aDOI Listing
September 2006

Phase II study of interferon-alpha and doxycycline for advanced renal cell carcinoma.

Invest New Drugs 2006 May;24(3):255-60

University of Wisconsin Comprehensive Cancer Center, K6/550 CSC, Madison, WI 53792, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-005-3903-zDOI Listing
May 2006

Phase I/II study of gemcitabine and exisulind as second-line therapy in patients with advanced non-small cell lung cancer.

J Thorac Oncol 2006 Mar;1(3):218-25

Ohio State University College of Medicine and Comprehensive Cancer Center, Columbus, Ohio, USA.

View Article

Download full-text PDF

Source
March 2006